VTYXライブシグナル | Getagraph.comで利益を最大化

売る 108132 min ago

@ $2.33

発行日: 14 2月 2024 @ 23:30

リターン: 65.24%

前回のシグナル: 2月 13 - 04:19

前回のシグナル: 買う

リターン: -6.99 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders...

Stats
本日の出来高	181 374
平均出来高	4.01M
時価総額	228.12M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.670 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.170
ATR14	$0.00900 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-12	Subramaniam Somu	Sell	695 339	Common Stock
2024-04-12	Nsv Partners Iii Lp	Sell	695 339	Common Stock
2024-04-02	Krueger Christopher W	Sell	1 651	Common Stock
2024-04-02	Nuss John	Sell	1 651	Common Stock
2024-04-02	Mohan Raju	Sell	4 312	Common Stock

INSIDER POWER
-9.38
Last 100 transactions
Buy: 2 083 814 \| Sell: 2 354 020

ボリューム相関

長: -0.07 (neutral)

短: 0.84 (strong)

Signal:(31.246) Same movement expected

Ventyx Biosciences, Inc. 相関

10 最も正の相関
SVRA	0.94
SY	0.936
IDCC	0.93
OVID	0.929
NVCN	0.929
HURC	0.926
OVLY	0.919
GPACU	0.919
VBOC	0.918
BYNOU	0.916

10 最も負の相関
NAKD	-0.93
PRPH	-0.91
ORPH	-0.903
CHKEL	-0.902
CSSEP	-0.902
PROC	-0.9
ALXO	-0.898
HCAQ	-0.897
TRIT	-0.895
AHPI	-0.892

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ventyx Biosciences, Inc. 相関 - 通貨/商品

-0.78
( moderate negative )

-0.86
( strong negative )

0.00
( neutral )

-0.66
( moderate negative )

Ventyx Biosciences, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-941 000 (0.00 %)
EPS:	$-3.30

FY	2023
収益:	$0
総利益:	$-941 000 (0.00 %)
EPS:	$-3.30

FY	2022
収益:	$0
総利益:	$-470 000 (0.00 %)
EPS:	$-2.06

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-6.65

Financial Reports:

No articles found.

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.